Wells Fargo lowered the firm’s price target on Calumet (CLMT) to $21 from $23 and keeps an Overweight rating on the shares. The firm says the Path to MaxSAF remains on schedule, but more importantly, significantly cheaper. Potential dispositions provide a bridge for any debt reduction, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls
- Calumet initiated with a Buy at BofA
- Positive Outlook for Calumet Specialty Products Driven by Operational Performance and Strategic Financial Maneuvers
- Calumet Specialty Products: Hold Rating Amid Rising Net Debt and Uncertain Earnings Outlook
- Calumet Specialty Products Reports Q1 2025 Results